<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287546</url>
  </required_header>
  <id_info>
    <org_study_id>13298</org_study_id>
    <secondary_id>I4C-MC-JTBA</secondary_id>
    <nct_id>NCT01287546</nct_id>
  </id_info>
  <brief_title>A Study of LY2875358 in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Study of LY2875358 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine a recommended Phase 2 dose range of LY2875358
      that may be safely administered to participants with advanced cancer. In Part A and Part A2
      of this study, escalating doses of LY2875358 as monotherapy and in combination with erlotinib
      will be evaluated for safety and tolerability, respectively. Part B is a dose-confirmation
      segment for LY2875358 therapy in 5 different types of cancer: nonsquamous non-small cell lung
      cancer (NSCLC), castrate resistant prostate cancer (CRPC) with bone metastases, renal cell
      carcinoma (RCC), hepatocellular carcinoma (HCC), or uveal melanoma with liver metastases, and
      for LY2875358 in combination with trametinib in participants with uveal melanoma with liver
      metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol amendment (November, 2013) expanded Part B to study LY2875358 in combination with
      trametinib in participants with uveal melanoma with liver metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2010</start_date>
  <completion_date type="Actual">October 26, 2016</completion_date>
  <primary_completion_date type="Actual">January 8, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 dose range of LY2875358 monotherapy and in combination with erlotinib</measure>
    <time_frame>Baseline through Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a tumor response</measure>
    <time_frame>Baseline to study completion (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression and overall survival</measure>
    <time_frame>Baseline to study completion (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC) of erlotinib or trametinib in combination with LY2875358</measure>
    <time_frame>Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Brief Pain Inventory (BPI) in Part B: Expansion Cohort 1</measure>
    <time_frame>Baseline to study completion (12 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>LY2875358</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2875358 + erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2875358 at Part A highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2875358 at Part A highest dose + trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358</intervention_name>
    <description>Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.</description>
    <arm_group_label>LY2875358</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358 + erlotinib</intervention_name>
    <description>Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).</description>
    <arm_group_label>LY2875358 + erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358 at Part A highest dose</intervention_name>
    <description>Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.</description>
    <arm_group_label>LY2875358 at Part A highest dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358 at Part A highest dose + trametinib</intervention_name>
    <description>Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily</description>
    <arm_group_label>LY2875358 at Part A highest dose + trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A: Have histological or cytological evidence of cancer (solid tumor, lymphoma, or
             multiple myeloma) that is advanced and/or metastatic and an appropriate candidate for
             experimental therapy

          -  Part A2: Histologic or cytologic diagnosis of advanced Non Small Cell Lung Cancer
             (NSCLC), Stage IIIB with malignant pleural effusion or Stage IV, completed at least 1
             prior systemic regimen, and eligible for erlotinib therapy.

          -  Part B: Candidate for experimental therapy after standard therapies used or
             non-eligible for standard therapies. Histological or cytological evidence of 1 of the
             5 tumor types:

          -  Castrate-resistant prostate cancer (CRPC) with bone metastasis:

             --Progressive Disease in the setting of castrate level of testosterone

          -  Renal Cell Carcinoma (RCC):

             --Histologic diagnosis of either clear-cell or papillary RCC (metastatic and
             unresectable, or bilateral, multifocal, unresectable RCC localized to kidneys).

          -  NSCLC:

             --Histologic or cytologic diagnosis of advanced NSCLC, Stage IIIB with malignant
             pleural effusion or Stage IV

          -  Hepatocellular Carcinoma (HCC)

             --Histologic or cytologic diagnosis of hepatocellular carcinoma

          -  Uveal Melanoma with liver metastasis

          -  Part A: Have the presence of measurable or nonmeasurable disease as defined by the
             RECIST v1.1 (Eisenhauer et al. 2009) or Revised Response Criteria for Malignant
             Lymphoma (Cheson et al. 2007) or have measureable disease for multiple myeloma.

          -  Part A2 &amp; B (RCC, NSCLC, HCC, and uveal melanoma): Have measurable disease as defined
             by RECIST v1.1.

          -  Give written informed consent prior to any study-specific procedures.

          -  Adequate organ function.

          -  Performance status of less than or equal to 2 on ECOG scale.

          -  Discontinued all previous cancer therapies, and any agents that have not received
             regulatory approval, for at least 21 days and recovered from the acute effects of
             therapy. Must have discontinued mitomycin-C or nitrosourea therapy for at least 42
             days.

          -  Reliable and available for the duration of the study and willing to follow study
             procedures.

          -  Males and females (reproductive potential): Use medically approved contraceptive
             precautions during the study and for 4 months following the last dose of study drug.

          -  Females (childbearing potential): Have had a negative serum pregnancy test before the
             first dose of study drug and not be breast-feeding.

          -  Estimated life expectancy that will permit the participants to complete 8 weeks of
             treatment.

        Exclusion Criteria:

          -  Serious preexisting medical conditions

          -  Symptomatic central nervous system malignancy or metastasis (screening not required).

          -  Acute or chronic leukemia.

          -  Active infection including HIV, hepatitis A, B or C

          -  Have second primary malignancy that may affect the interpretation of results.

          -  Have received a liver transplant, or have liver cirrhosis with a Child-Pugh Stage of B
             or C.

          -  Patients with active alcohol abuse, as determined by the treating investigator.

          -  Part A2: Unable to swallow tablets. Intolerant of therapy with erlotinib. Concomitant
             treatment with the cytochrome P450 3A (CYP3A) modulators. Must not have received
             treatment with any of these modulators within 14 days of study treatment.

          -  Have a history of New York Heart Association class â‰¥3, unstable angina, myocardial
             infarction 6 months prior to study drug

          -  QTc greater than 470 msec.

          -  Received previous treatment with any c-MET experimental therapeutic.

          -  Part B Expansion Cohort 1 (CRPC):

               1. Increasing use of daily doses of opioid analgesics within 28 days prior to
                  enrollment in the study.

               2. Neuroendocrine prostate cancer.

               3. Patients who have a solitary bone metastasis that has been irradiated are not
                  eligible.

          -  Part B Expansion Cohort 6 (LY2875358 plus trametinib in participants with uveal
             melanoma with liver metastasis): Contra-indications for trametinib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-5615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic of Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

